Showing results (1-10 of 59) with videos related to
Sort By:
Pageof 6
Annals of the New York Academy of Sciences|February 10, 2000
Farnesyltransferase inhibitors. Preclinical developmentN E KohlOncogene|January 1, 1987
Role of c-myc in the transformation of REF52 cells by viral and cellular oncogenesN E Kohl, H E RuleyCancer Metastasis Reviews|October 14, 1998
Pre-clinical development of farnesyltransferase inhibitorsR B Lobell, N E KohlTrends in Pharmacological Sciences|January 14, 1998
CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agentsC A Omer, N E KohlScience (New York, N.Y.)|December 14, 1984
Activated expression of the N-myc gene in human neuroblastomas and related tumorsN E Kohl, C E Gee, F W AltOncogene|February 1, 1991
Massive accumulation of neutral lipids in cells conditionally transformed by an activated H-ras oncogeneT Hirakawa, K Maruyama, N E Kohl, et al.Methods in Molecular Biology (Clifton, N.J.)|July 17, 1998
Biochemical and biological analyses of farnesyl-protein transferase inhibitorsN E Kohl, K S Koblan, C A Omer, et al.Carcinogenesis|January 1, 1981
The formation of azoxy-2-phenylethane during the biological oxidation of phenylethylamine by rabbit liver microsomesE S Fiala, N E Kohl, S S Hecht, et al.Cancer Chemotherapy and Pharmacology|July 27, 2000
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utilityF M Sirotnak, L Sepp-Lorenzino, N E Kohl, et al.Cancer Research|June 1, 1996
Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitorsG C Prendergast, J P Davide, P F Lebowitz, et al.Pageof 6